Literature DB >> 19734429

Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.

Sandrine Hayette, Kaddour Chabane, Andrei Tchirkov, Marc G Berger, Franck E Nicolini, Olivier Tournilhac.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19734429      PMCID： PMC2738731          DOI： 10.3324/haematol.2009.007864

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.

Authors:  Sandrine Hayette; Mauricette Michallet; Marie-Laurence Baille; Jean-Pierre Magaud; Franck E Nicolini
Journal:  Leuk Res       Date:  2005-03-23       Impact factor: 3.156

2.  A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.

Authors:  F X Gruber; H Hjorth-Hansen; I Mikkola; L Stenke; T Johansen
Journal:  Leukemia       Date:  2006-09-28       Impact factor: 11.528

3.  Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).

Authors:  F E Nicolini; S Corm; Q-H Lê; N Sorel; S Hayette; D Bories; T Leguay; L Roy; S Giraudier; M Tulliez; T Facon; F-X Mahon; J-M Cayuela; P Rousselot; M Michallet; C Preudhomme; F Guilhot; C Roche-Lestienne
Journal:  Leukemia       Date:  2006-06       Impact factor: 11.528

4.  Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

Authors:  Susan Branford; Zbigniew Rudzki; Sonya Walsh; Ian Parkinson; Andrew Grigg; Jeff Szer; Kerry Taylor; Richard Herrmann; John F Seymour; Chris Arthur; David Joske; Kevin Lynch; Tim Hughes
Journal:  Blood       Date:  2003-03-06       Impact factor: 22.113

5.  ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Giovanni Martinelli; Gianantonio Rosti; Simona Bassi; Marilina Amabile; Angela Poerio; Barbara Giannini; Elena Trabacchi; Fausto Castagnetti; Nicoletta Testoni; Simona Luatti; Antonio de Vivo; Daniela Cilloni; Barbara Izzo; Milena Fava; Elisabetta Abruzzese; Daniele Alberti; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

6.  Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.

Authors:  E Jabbour; H Kantarjian; D Jones; M Talpaz; N Bekele; S O'Brien; X Zhou; R Luthra; G Garcia-Manero; F Giles; M B Rios; S Verstovsek; J Cortes
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

7.  Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.

Authors:  Franck E Nicolini; Sandrine Hayette; Selim Corm; Emmanuel Bachy; Dominique Bories; Michel Tulliez; François Guilhot; Laurence Legros; Frédéric Maloisel; Jean-Jacques Kiladjian; François-Xavier Mahon; Quoc-Hung Lê; Mauricette Michallet; Catherine Roche-Lestienne; Claude Preudhomme
Journal:  Haematologica       Date:  2007-09       Impact factor: 9.941

8.  BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.

Authors:  Tai-Sung Lee; Wanlong Ma; Xi Zhang; Francis Giles; Jorge Cortes; Hagop Kantarjian; Maher Albitar
Journal:  Mol Cancer Ther       Date:  2008-12-03       Impact factor: 6.261

Review 9.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

10.  Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.

Authors:  Thomas Ernst; Philipp Erben; Martin C Müller; Peter Paschka; Thomas Schenk; Jana Hoffmann; Sebastian Kreil; Paul La Rosée; Rüdiger Hehlmann; Andreas Hochhaus
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941
View more
  1 in total

1.  A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.

Authors:  Katsuya Sakai; Yuichi Ishikawa; Yumiko Mori; Miki Kobayashi; Chisako Iriyama; Yukiyasu Ozawa; Tatsuya Suzuki; Yosuke Minami; Kazuhiro Ishikawa; Norio Kaneda; Tomoki Naoe; Hitoshi Kiyoi
Journal:  Int J Hematol       Date:  2011-01-25       Impact factor: 2.490
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.